If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-28. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Carrey reunited with Joel Schumacher, director of Batman Forever, for The Number 23 (2007), a psychological thriller co-starring Virginia Madsen and Danny Huston. In the film, Carrey plays a man who becomes obsessed with the number 23, after finding a book about a man with the same obsession. The film was panned by critics. The following year Carrey provided his voice for Dr. Seuss' Horton Hears a Who! (2008). Carrey voiced Horton the Elephant for the CGI-animated feature, which was a box office success, grossing over $290 million worldwide. Carrey returned to live-action comedy, starring opposite Zooey Deschanel and Bradley Cooper in Yes Man (also 2008). Carrey played a man who signs up for a self-help program that teaches him to say yes to everything. Despite reviews being mixed, Rene Rodriquez of The Miami Herald stated, "Yes Man is fine as far as Jim Carrey comedies go, but it's even better as a love story that just happens to make you laugh." The film earned $225 million at the box office worldwide.
The Parliamentary Commission on Standards finds that Lord Waheed Alli committed four minor breaches in the register of members' interests. 24 October – Chancellor Rachel Reeves announces the UK government is to change its self-imposed debt rules in order to make an extra £50bn available for spending at the forthcoming budget. Lee Waters announces he will step down from the Senedd at the 2026 election. 26 October – Commonwealth leaders agree the "time has come" for a conversation about reparations for the slave trade, despite the UK's wish to keep the topic off the agenda at the Commonwealth Heads of Government Meeting. Buckingham Palace announces that Charles III is expected to return to a "normal" schedule in 2025 after his trip to the Commonwealth summit proved to be a "perfect tonic". A video emerges that appears to show Mike Amesbury, the MP for Runcorn and Helsby, shouting and swearing at a man who is lying on the ground during an apparent disturbance. Secretary of State for Wales Jo Stevens is accused by the Conservatives of bringing her office into disrepute after recording a political interview on its premises, something which they say breaches the civil service code. 28 October – The speaker of the House of Commons, Lindsay Hoyle, reprimands the chancellor, Rachel Reeves, in the Commons for giving information to journalists in the US about the upcoming Budget, in potential contravention of the ministerial code, which expects major government announcements to be made in the Commons before to the news media.
TIMPs inhibit all MMPs except TIMP-1 which does not inhibit MT-1-MMP. There are some differences in the inhibitory preferences of TIMPs. TIMP-1 for example favors to inhibit MMP-9. Other examples are TIMP-2 and TIMP-4 which are more potent MMP-2 inhibitors than MMP-9 inhibitors. TIMPs could potentially be useful against illnesses like cardiovascular disease and cancer. The application of TIMPs as therapeutic instrument through gene therapy or direct protein application is still in early stages of development. It is preferable to inhibit specific MPPs that play a role in pathological conditions. Since TIMPs inhibit multiple MMPs it is desirable to develop engineered TIMPs with altered specificity.
US Health Physics Society United Nations "Human rights and weapons of mass destruction, or with indiscriminate effect, or of a nature to cause superfluous injury or unnecessary suffering" (The UN 2002 report) Depleted Uranium and the IAEA Scientific reports ATSDR – Case Studies in Environmental Medicine (CSEM): Uranium Toxicity Archived 4 February 2016 at the Wayback Machine U.S. Department of Health and Human Services "Depleted Uranium in Bosnia and Herzegovina – Postconflict Assessment" Archived 25 February 2012 at the Wayback Machine by UN Environment Programme "Radiological Conditions in Areas of Kuwait With Residues of Depleted Uranium" by International Atomic Energy Agency "Technical Report on Capacity-building for the Assessment of Depleted Uranium in Iraq" Archived 9 March 2012 at the Wayback Machine by UN Environment Programme "A Review of the Scientific Literature As It Pertains to Gulf War Illnesses" by RAND Depleted Uranium article from the Royal Society (archived) An Analysis of Uranium Dispersal and Health Effects Using a Gulf War Case Study by Sandia National Laboratories Depleted Uranium Human Health Fact Sheet by Argonne National Laboratory Environmental Assessment Division Depleted uranium (DU) normative value pilot study: levels of uranium in urine samples from the general population Archived 26 July 2011 at the Wayback Machine by A.D. Jones, B. G. Miller, S. Walker, J. Anderson, A. P. Colvin, P.A. Hutchison, C.A. Soutar.
Sources: en.wikipedia.org
==== Antistatic agents ==== Ionic surfactants also function as external antistatic agents to prevent electrostatic charging of plastic surfaces (ESD protection). Both anionic and cationic surfactants are used for this purpose[9].
=== Churches === Le Havre Cathedral: the first stone of the building was laid in 1536. It is the seat of the Bishop of Le Havre. Church of Saint Joseph, one of the most recognized symbols of the city. The belltower is one of the tallest in France, rising to a height of 107 metres. It was designed by Auguste Perret. Church of Saint Michel Church of Saint Vincent Church of Saint François Church of St. Anne Church of Saint Marie Chapel of Saint Michel d'Ingouville (15th century) Graville Abbey, a monastery dedicated to Sainte Honorine, set in grounds on the northern bank of the Seine River. Presbyterian Reform Church (Église Réformée), 47 rue Anatole France, built in 1857, bombed in 1941, the roof and ceiling were rebuilt in 1953 by two architects from the famous Auguste Perret office: Jacques Lamy and Gérard Dupasquier, The only building in town offering both ancient and the new Perret school of architecture in the same building. Holy Office each Sunday morning at 10.30.
== Application == B1H system provides a tool in our arsenal for identifying the DNA-binding specificities of transcription factors and thus predicting their target genes and genomic DNA regulatory elements. It also allows for examination of the effects of protein–protein interactions on DNA binding, which may further guide the prediction of cis regulatory modules based on binding-site clustering. Moreover, the B1H selection system has implications for the predicting regulatory roles of previously uncharacterized transcription factors.
He followed this result with a semifinals showing in Beijing, losing to Danill Medvedev in their 5th meeting of the year. Unable to maintain his form, he lost in the second round of the Shanghai Masters against Roman Safiullin, where he was the defending finalist from 2019, and lost to Jordan Thompson in Tokyo. During the European indoor hardcourt season, Zverev made the quarterfinals in Vienna before losing to Andrey Rublev in three sets and reached the third round in Paris, losing to Stefanos Tsitsipas. Despite this, he qualified for the ATP Finals for the first time since 2021. At the event, he was drawn in the red group and defeated Carlos Alcaraz in three sets and Andrey Rublev in straight sets whilst losing to Medvedev. He failed to qualify for the semifinals after Alcaraz and Medvedev were more successful in terms of win-loss percentage in sets, ending his 2023 season.
=== Diagnostic criteria === An international group created a set of criteria for the diagnosis of primary Sjögren's disease in 2016 based on consensus around previous guidelines from the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR), which became known as the ACR-EULAR criteria. Although used primarily for recruitment into clinical trials, the criteria were shown to be effective in diagnosing Sjögren's by a 2025 Swedish cohort study. Per the ACR-EULAR criteria, a person with previously reported dry eye or dry mouth symptoms (including if responding positively to a short questionnaire) has SjD if they have a score of at least 4 when considering the following items:
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.